| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Echocardiography | 20 | 2021 | 911 | 1.990 |
Why?
|
| Ventricular Dysfunction, Left | 6 | 2019 | 318 | 1.260 |
Why?
|
| Ventricular Function, Left | 13 | 2021 | 592 | 1.170 |
Why?
|
| Point-of-Care Systems | 5 | 2020 | 141 | 1.080 |
Why?
|
| Trastuzumab | 2 | 2016 | 68 | 1.060 |
Why?
|
| Heart Diseases | 8 | 2022 | 290 | 1.020 |
Why?
|
| Heart Valve Diseases | 2 | 2024 | 109 | 0.910 |
Why?
|
| Aortic Diseases | 1 | 2024 | 100 | 0.910 |
Why?
|
| Cardiotoxicity | 2 | 2021 | 9 | 0.890 |
Why?
|
| Cardiology | 5 | 2023 | 123 | 0.880 |
Why?
|
| Heart Neoplasms | 2 | 2022 | 62 | 0.870 |
Why?
|
| Stroke Volume | 7 | 2021 | 456 | 0.850 |
Why?
|
| Antineoplastic Agents | 6 | 2022 | 2360 | 0.790 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 86 | 0.790 |
Why?
|
| Anthracyclines | 2 | 2019 | 37 | 0.690 |
Why?
|
| Medical Oncology | 7 | 2023 | 359 | 0.680 |
Why?
|
| Artificial Intelligence | 3 | 2022 | 298 | 0.670 |
Why?
|
| Cardiovascular Diseases | 8 | 2022 | 827 | 0.640 |
Why?
|
| Cardiomyopathies | 3 | 2016 | 240 | 0.600 |
Why?
|
| Radiation Protection | 1 | 2016 | 25 | 0.550 |
Why?
|
| Cardiology Service, Hospital | 1 | 2015 | 4 | 0.540 |
Why?
|
| Oncology Service, Hospital | 1 | 2015 | 6 | 0.540 |
Why?
|
| Radionuclide Imaging | 1 | 2016 | 220 | 0.540 |
Why?
|
| Cardiac Volume | 1 | 2015 | 53 | 0.520 |
Why?
|
| Taxoids | 1 | 2015 | 129 | 0.510 |
Why?
|
| Breast Neoplasms | 3 | 2023 | 2903 | 0.500 |
Why?
|
| Myocardial Ischemia | 6 | 2005 | 162 | 0.490 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 878 | 0.490 |
Why?
|
| Echocardiography, Doppler, Color | 5 | 2004 | 103 | 0.460 |
Why?
|
| Physical Examination | 3 | 2020 | 149 | 0.450 |
Why?
|
| Academic Medical Centers | 2 | 2015 | 379 | 0.450 |
Why?
|
| Heart Ventricles | 3 | 2016 | 760 | 0.430 |
Why?
|
| Echocardiography, Stress | 4 | 2005 | 20 | 0.420 |
Why?
|
| Humans | 55 | 2024 | 86643 | 0.410 |
Why?
|
| Phenethylamines | 2 | 2000 | 6 | 0.390 |
Why?
|
| Ultrasonography | 5 | 2020 | 695 | 0.390 |
Why?
|
| Potassium Channel Blockers | 2 | 2000 | 64 | 0.380 |
Why?
|
| Neoplasms | 6 | 2023 | 2898 | 0.380 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2000 | 58 | 0.370 |
Why?
|
| Echocardiography, Three-Dimensional | 4 | 2021 | 516 | 0.350 |
Why?
|
| Heart Failure | 1 | 2019 | 1204 | 0.350 |
Why?
|
| Mitral Valve | 3 | 2005 | 248 | 0.330 |
Why?
|
| Sulfonamides | 2 | 2000 | 300 | 0.330 |
Why?
|
| Surveys and Questionnaires | 1 | 2016 | 2501 | 0.310 |
Why?
|
| Myocardial Contraction | 5 | 2004 | 244 | 0.310 |
Why?
|
| United States | 8 | 2024 | 6672 | 0.280 |
Why?
|
| Image Enhancement | 4 | 2005 | 563 | 0.280 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2005 | 160 | 0.270 |
Why?
|
| Heart Atria | 3 | 2021 | 250 | 0.260 |
Why?
|
| Early Diagnosis | 2 | 2018 | 131 | 0.260 |
Why?
|
| Echocardiography, Transesophageal | 7 | 2021 | 344 | 0.240 |
Why?
|
| Cardiologists | 1 | 2023 | 4 | 0.240 |
Why?
|
| Atrial Flutter | 2 | 2000 | 33 | 0.240 |
Why?
|
| Multimodal Imaging | 2 | 2014 | 110 | 0.240 |
Why?
|
| Sensitivity and Specificity | 9 | 2008 | 1991 | 0.240 |
Why?
|
| Atrial Function, Left | 2 | 2021 | 46 | 0.240 |
Why?
|
| American Heart Association | 1 | 2024 | 92 | 0.230 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2004 | 87 | 0.230 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2005 | 663 | 0.230 |
Why?
|
| Movement | 1 | 2005 | 299 | 0.230 |
Why?
|
| Inservice Training | 1 | 2003 | 38 | 0.230 |
Why?
|
| Electric Countershock | 2 | 2000 | 47 | 0.230 |
Why?
|
| Aorta | 1 | 2004 | 280 | 0.230 |
Why?
|
| Atrial Fibrillation | 3 | 2000 | 288 | 0.210 |
Why?
|
| Exercise Test | 1 | 2003 | 164 | 0.210 |
Why?
|
| Women's Health | 1 | 2003 | 100 | 0.210 |
Why?
|
| Transillumination | 1 | 2021 | 9 | 0.200 |
Why?
|
| Thrombosis | 3 | 2016 | 296 | 0.200 |
Why?
|
| Algorithms | 4 | 2019 | 1830 | 0.200 |
Why?
|
| Electrocardiography | 2 | 2003 | 478 | 0.200 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2022 | 138 | 0.200 |
Why?
|
| Radiopharmaceuticals | 1 | 2022 | 180 | 0.190 |
Why?
|
| Tachycardia | 1 | 2000 | 35 | 0.190 |
Why?
|
| Consensus | 3 | 2020 | 335 | 0.190 |
Why?
|
| Contrast Media | 7 | 2005 | 1078 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2022 | 2601 | 0.190 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 199 | 0.190 |
Why?
|
| Heart Conduction System | 1 | 2000 | 108 | 0.180 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2021 | 187 | 0.180 |
Why?
|
| Nuclear Family | 1 | 2019 | 92 | 0.170 |
Why?
|
| Diagnostic Errors | 2 | 2014 | 160 | 0.170 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2019 | 114 | 0.170 |
Why?
|
| Female | 23 | 2023 | 44532 | 0.170 |
Why?
|
| Thrombolytic Therapy | 2 | 2016 | 220 | 0.160 |
Why?
|
| Hemothorax | 1 | 2018 | 15 | 0.160 |
Why?
|
| Heart Massage | 1 | 2018 | 12 | 0.160 |
Why?
|
| Coronary Artery Disease | 1 | 2003 | 350 | 0.160 |
Why?
|
| Ventricular Fibrillation | 1 | 2018 | 65 | 0.160 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2016 | 159 | 0.150 |
Why?
|
| Genetic Association Studies | 1 | 2019 | 294 | 0.150 |
Why?
|
| Diagnostic Imaging | 1 | 2021 | 469 | 0.150 |
Why?
|
| Pedigree | 1 | 2019 | 966 | 0.150 |
Why?
|
| Oligopeptides | 1 | 2017 | 179 | 0.140 |
Why?
|
| Anticoagulants | 2 | 2018 | 408 | 0.140 |
Why?
|
| Parents | 1 | 2019 | 272 | 0.140 |
Why?
|
| Risk Factors | 5 | 2019 | 5417 | 0.140 |
Why?
|
| Radiation, Ionizing | 1 | 2016 | 121 | 0.140 |
Why?
|
| Predictive Value of Tests | 5 | 2021 | 1673 | 0.130 |
Why?
|
| Myocardium | 4 | 2011 | 529 | 0.130 |
Why?
|
| Pandemics | 1 | 2021 | 740 | 0.130 |
Why?
|
| Societies, Medical | 2 | 2016 | 572 | 0.130 |
Why?
|
| Radiation Dosage | 1 | 2016 | 227 | 0.130 |
Why?
|
| Phenotype | 2 | 2019 | 2378 | 0.130 |
Why?
|
| Heart Arrest | 1 | 2018 | 265 | 0.120 |
Why?
|
| Incidence | 3 | 2016 | 1577 | 0.120 |
Why?
|
| Image Processing, Computer-Assisted | 7 | 2005 | 1204 | 0.120 |
Why?
|
| Documentation | 1 | 2014 | 98 | 0.120 |
Why?
|
| Feasibility Studies | 6 | 2005 | 751 | 0.120 |
Why?
|
| Internship and Residency | 1 | 2003 | 1004 | 0.120 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2014 | 103 | 0.120 |
Why?
|
| Male | 22 | 2018 | 40965 | 0.120 |
Why?
|
| Tunica Intima | 3 | 2008 | 59 | 0.120 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 307 | 0.110 |
Why?
|
| Pulmonary Embolism | 1 | 2016 | 222 | 0.110 |
Why?
|
| Echocardiography, Doppler | 2 | 2003 | 187 | 0.110 |
Why?
|
| Genome-Wide Association Study | 2 | 2019 | 1621 | 0.100 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 369 | 0.100 |
Why?
|
| Quantitative Trait Loci | 1 | 2016 | 576 | 0.100 |
Why?
|
| Chemoradiotherapy | 1 | 2014 | 301 | 0.100 |
Why?
|
| Middle Aged | 14 | 2018 | 25028 | 0.100 |
Why?
|
| Radiology | 2 | 2014 | 194 | 0.100 |
Why?
|
| Office Visits | 2 | 2008 | 44 | 0.100 |
Why?
|
| Risk Assessment | 3 | 2008 | 2261 | 0.100 |
Why?
|
| Sarcoidosis | 1 | 2011 | 71 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2014 | 428 | 0.090 |
Why?
|
| Aged | 12 | 2017 | 18415 | 0.090 |
Why?
|
| Myocardial Infarction | 2 | 2003 | 376 | 0.090 |
Why?
|
| Swine | 4 | 2004 | 555 | 0.090 |
Why?
|
| Systole | 2 | 2011 | 129 | 0.090 |
Why?
|
| Clinical Trials as Topic | 2 | 2009 | 1169 | 0.090 |
Why?
|
| Heart | 3 | 2021 | 539 | 0.090 |
Why?
|
| Biomarkers | 2 | 2014 | 1718 | 0.090 |
Why?
|
| Equipment Design | 3 | 2005 | 406 | 0.090 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2009 | 73 | 0.090 |
Why?
|
| Clinical Competence | 2 | 2005 | 751 | 0.080 |
Why?
|
| Fluorocarbons | 3 | 2003 | 72 | 0.080 |
Why?
|
| Carotid Artery, Common | 1 | 2008 | 29 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 1 | 2009 | 220 | 0.080 |
Why?
|
| Retrospective Studies | 1 | 2021 | 8489 | 0.080 |
Why?
|
| Carotid Artery Diseases | 1 | 2008 | 97 | 0.080 |
Why?
|
| Prevalence | 3 | 2011 | 1239 | 0.080 |
Why?
|
| Professional Competence | 1 | 2007 | 68 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 2271 | 0.070 |
Why?
|
| Endocardium | 2 | 2004 | 76 | 0.070 |
Why?
|
| Carotid Stenosis | 1 | 2007 | 112 | 0.070 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2003 | 73 | 0.070 |
Why?
|
| Cholesterol | 1 | 2008 | 356 | 0.070 |
Why?
|
| Dipyridamole | 1 | 2005 | 14 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2008 | 2705 | 0.070 |
Why?
|
| Esophageal Perforation | 1 | 2005 | 18 | 0.070 |
Why?
|
| Echocardiography, Doppler, Pulsed | 2 | 2002 | 23 | 0.070 |
Why?
|
| Health Personnel | 1 | 2007 | 202 | 0.070 |
Why?
|
| Puerperal Disorders | 1 | 2005 | 32 | 0.070 |
Why?
|
| Pericardial Effusion | 1 | 2004 | 19 | 0.060 |
Why?
|
| Adult | 10 | 2014 | 25648 | 0.060 |
Why?
|
| Vasodilator Agents | 1 | 2005 | 152 | 0.060 |
Why?
|
| Ventricular Dysfunction | 2 | 2004 | 28 | 0.060 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2005 | 104 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 307 | 0.060 |
Why?
|
| Skin | 1 | 2008 | 554 | 0.060 |
Why?
|
| Myxoma | 1 | 2004 | 28 | 0.060 |
Why?
|
| Urban Health Services | 1 | 2004 | 45 | 0.060 |
Why?
|
| Coronary Disease | 1 | 2005 | 261 | 0.060 |
Why?
|
| Mitral Valve Stenosis | 1 | 2003 | 37 | 0.060 |
Why?
|
| Hospitals, General | 1 | 2003 | 12 | 0.060 |
Why?
|
| Dobutamine | 1 | 2003 | 61 | 0.060 |
Why?
|
| Blood Flow Velocity | 2 | 2002 | 197 | 0.060 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2003 | 7 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 159 | 0.060 |
Why?
|
| Heart Function Tests | 1 | 2003 | 30 | 0.060 |
Why?
|
| Educational Measurement | 1 | 2005 | 225 | 0.060 |
Why?
|
| Aortic Valve | 1 | 2004 | 222 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2005 | 912 | 0.060 |
Why?
|
| Physician-Patient Relations | 1 | 2008 | 610 | 0.060 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2008 | 582 | 0.060 |
Why?
|
| Streptokinase | 1 | 2001 | 12 | 0.050 |
Why?
|
| Heart Rate | 2 | 2003 | 492 | 0.050 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2002 | 42 | 0.050 |
Why?
|
| Aortic Valve Stenosis | 1 | 2003 | 131 | 0.050 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2003 | 134 | 0.050 |
Why?
|
| Heart Valve Prosthesis | 1 | 2001 | 93 | 0.050 |
Why?
|
| Expert Testimony | 1 | 2021 | 46 | 0.050 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2003 | 187 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2003 | 1801 | 0.050 |
Why?
|
| Food-Drug Interactions | 1 | 2000 | 18 | 0.050 |
Why?
|
| Primary Health Care | 1 | 2004 | 339 | 0.050 |
Why?
|
| Random Allocation | 1 | 2020 | 332 | 0.050 |
Why?
|
| Students, Medical | 1 | 2005 | 384 | 0.050 |
Why?
|
| Electrophysiology | 1 | 2000 | 401 | 0.040 |
Why?
|
| Registries | 1 | 2023 | 702 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2001 | 202 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2021 | 4213 | 0.040 |
Why?
|
| Sex Factors | 1 | 2003 | 1054 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2019 | 2357 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2000 | 916 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 294 | 0.040 |
Why?
|
| Acoustics | 3 | 2003 | 51 | 0.040 |
Why?
|
| Tunica Media | 2 | 2008 | 16 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 1565 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2019 | 476 | 0.040 |
Why?
|
| Animals | 5 | 2004 | 26582 | 0.040 |
Why?
|
| Recurrence | 1 | 2000 | 1139 | 0.040 |
Why?
|
| Observer Variation | 3 | 2004 | 602 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 2 | 2014 | 1036 | 0.040 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2016 | 38 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2000 | 1823 | 0.030 |
Why?
|
| Canada | 1 | 2016 | 204 | 0.030 |
Why?
|
| Alleles | 1 | 2019 | 1128 | 0.030 |
Why?
|
| Interprofessional Relations | 1 | 2016 | 121 | 0.030 |
Why?
|
| Emergency Medical Services | 1 | 2018 | 209 | 0.030 |
Why?
|
| Computer Systems | 1 | 2014 | 79 | 0.030 |
Why?
|
| Europe | 1 | 2014 | 309 | 0.030 |
Why?
|
| Coronary Circulation | 2 | 2004 | 130 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2019 | 926 | 0.030 |
Why?
|
| Pattern Recognition, Automated | 1 | 2014 | 217 | 0.030 |
Why?
|
| Microspheres | 2 | 2003 | 101 | 0.030 |
Why?
|
| Reference Values | 2 | 2004 | 674 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 456 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2008 | 6509 | 0.020 |
Why?
|
| Tachycardia, Ventricular | 1 | 2011 | 115 | 0.020 |
Why?
|
| Age Factors | 2 | 2004 | 1851 | 0.020 |
Why?
|
| Wisconsin | 1 | 2008 | 39 | 0.020 |
Why?
|
| Ultrasonography, Doppler | 1 | 2007 | 80 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 1920 | 0.020 |
Why?
|
| Health Behavior | 1 | 2008 | 183 | 0.020 |
Why?
|
| Motivation | 1 | 2008 | 287 | 0.020 |
Why?
|
| Medically Underserved Area | 1 | 2004 | 25 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2005 | 232 | 0.020 |
Why?
|
| Myocardial Reperfusion | 1 | 2004 | 27 | 0.020 |
Why?
|
| Illinois | 1 | 2005 | 462 | 0.020 |
Why?
|
| Transducers | 1 | 2003 | 41 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2003 | 216 | 0.010 |
Why?
|
| Computing Methodologies | 1 | 2002 | 9 | 0.010 |
Why?
|
| ROC Curve | 1 | 2005 | 752 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2004 | 238 | 0.010 |
Why?
|
| Patient Admission | 1 | 2003 | 112 | 0.010 |
Why?
|
| Minority Groups | 1 | 2004 | 137 | 0.010 |
Why?
|
| Adolescent | 2 | 2005 | 8981 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2002 | 92 | 0.010 |
Why?
|
| Albumins | 1 | 2002 | 133 | 0.010 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2002 | 97 | 0.010 |
Why?
|
| Chicago | 1 | 2003 | 1379 | 0.010 |
Why?
|
| Software | 1 | 2002 | 654 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2005 | 3640 | 0.010 |
Why?
|
| Pregnancy | 1 | 2005 | 2894 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2002 | 1805 | 0.010 |
Why?
|
| Prognosis | 1 | 2005 | 3679 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2002 | 2232 | 0.010 |
Why?
|
| Time Factors | 1 | 2003 | 5210 | 0.010 |
Why?
|